Lactoferrin para Recurrent Infections

A Evidências Vários grandes ensaios clínicos mostram de forma consistente benefícios significativos.

Meta-analysis shows lactoferrin supplementation may reduce the odds of respiratory tract infections by 40-45%. A 90-day RCT demonstrated 58% reduction in respiratory infections versus placebo. Neonatal trial showed late-onset sepsis at 5.9% with lactoferrin versus 17.3% control.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dlactoferrin\u0026condition\u003Drecurrent\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Conclusão

Key Study Findings

Case Reports n=1

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant.

Dose: None vs: None Outcome: None Efeito: None None

População: Patient with specific granule deficiency

Randomized Controlled Trial n=48 26.0 weeks Double-blind

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, …

Dose: 500 mg vs: Placebo Outcome: Disease remission Efeito: None None

População: None

In Vitro

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus.

Dose: None vs: Conventional antibiotics Outcome: Killing efficacy against extra- and intracellular S. aureus Efeito: None None

População: In vitro S. aureus cultures

Observational Study

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study.

Dose: None vs: Healthy controls Outcome: Antibacterial peptide levels in Crohn's disease Efeito: Decreased defensin and LL-37 in Crohn's patients None

População: Crohn's disease patients

In Vitro

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10.

Dose: None vs: None Outcome: immune function Efeito: None None

População: animal model

Other n=14 52.0 weeks

Abnormal nasal glandular secretion in recurrent sinusitis.

Dose: 25 mg vs: baseline Outcome: oxidative stress markers Efeito: or 2 None

População: general population

Key Statistics

Estudos

2000

Participantes

↑

Positive

Nota

Referenced Papers

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. Case Report

Pediatric allergy, immunology, … 2022 4 citações

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. RCT

Beneficial microbes 2019 82 citações

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. Other

Antimicrobial agents and … 2013 115 citações

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Other

Lancet (London, England) 2002 519 citações

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. Other

Cellular immunology 1991 9 citações

Abnormal nasal glandular secretion in recurrent sinusitis. Other

The Journal of … 1990 50 citações

Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. Other

Annals of allergy 1985 1 citações

Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Other

Blood 1982

Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … Other

The American journal … 1980 138 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:: 100-200 mg/day
immunesupport:: 200-600 mg/day

Limite superior: No established UL; well-tolerated up to 1,200 mg/day

Dosagens Estudadas em Pesquisas

Dosagem	Duração	Efeito	N
None	--	Mixed	1
500 mg	26.0 weeks	Positive	48
None	--	Positive	--
None	--	Negative	--
None	--	Neutral	--
25 mg	52.0 weeks	Mixed	14
None	--	Positive	60
None	468.0 weeks	Mixed	--

Melhor horário: On empty stomach

Safety & Side Effects

Efeitos Colaterais Relatados

⚠ Generally very well tolerated
⚠ Mild gastrointestinal effects at high doses
⚠ Allergic reactions in those with cow's milk allergy
⚠ Constipation (rare, due to iron-binding)

Interações Conhecidas

● May enhance absorption of certain antibiotics
● May interact with iron supplements (iron-binding properties)

Ingestão máxima tolerável: No established UL; well-tolerated up to 1,200 mg/day

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Lactoferrin help with Recurrent Infections?

Based on 8 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Lactoferrin may support Recurrent Infections management. Our evidence grade is A (Strong Evidence).

How much Lactoferrin should I take for Recurrent Infections?

Studies have used various dosages. A commonly studied range is 100-200 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Lactoferrin?

Reported side effects may include Generally very well tolerated, Mild gastrointestinal effects at high doses, Allergic reactions in those with cow's milk allergy, Constipation (rare, due to iron-binding). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Lactoferrin and Recurrent Infections?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 8 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Outros ingredientes para Recurrent Infections

Bovine Colostrum B

Veredito Rápido

Evidence Strength92%

High confidence

Detalhamento dos Estudos

RCT (1)Meta (0)Other (7)

Comparar Alternativas

Veja como outros ingredientes se comparam para esta condição.

Ver todos os ingredientes para Recurrent Infections

Saiba Mais

References

[1] Zeynep Kihtir et al.. Pediatr Allergy Immunol Pulmonol. 2022. Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. doi:10.1089/ped.2021.0070 PubMed
[2] R Russo et al.. Benef Microbes. 2019. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. doi:10.3920/BM2018.0075 PubMed
[3] Jabeen Noore et al.. Antimicrob Agents Chemother. 2013. Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. doi:10.1128/AAC.01650-12 PubMed
[4] Katrin Pütsep et al.. Lancet. 2002. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. doi:10.1016/S0140-6736(02)11201-3 PubMed
[5] C C Brown et al.. Cell Immunol. 1991. Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. doi:10.1016/0008-8749(91)90010-9 PubMed
[6] E V Jeney et al.. J Allergy Clin Immunol. 1990. Abnormal nasal glandular secretion in recurrent sinusitis. doi:10.1016/s0091-6749(05)80117-4 PubMed
[7] J Pryjma et al.. Ann Allergy. 1985. Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. PubMed
[8] J I Gallin et al.. Blood. 1982. Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. PubMed
[9] J Breton-Gorius et al.. Am J Pathol. 1980. Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … PubMed

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.